1. Compound (I) for the treatment of a disease of the central nervous system, characterized in that Compound (I) is administered twice a week, weekly or every two weeks in a dose corresponding to from 20 mg / week to 50 mg / week in terms of free base of Compound (I) .2. Compound (I) according to claim 1, wherein Compound (I) is administered weekly at a dose based on the free base of Compound (I) between 20 mg / dose and 50 mg / dose. 3. Compound (I) according to claim 1 or 2, wherein Compound (I) is administered weekly at a dose calculated on the free base of Compound (I) between about 30 mg / dose and about 45 mg / dose. Compound (I) according to claim 1 or 2, wherein Compound (I) is administered weekly at a dose, based on the free base of Compound (I), of approximately 30 mg / dose. Compound (I) according to claim 1 or 2, wherein Compound (I) is administered weekly at a dose, based on the free base of Compound (I), approximately 45 mg / dose. The compound (I) for treatment according to claim 1, wherein the disease is selected from the group of diseases consisting of psychosis, in particular schizophrenia, or other diseases having psychotic symptoms, such as, for example, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, short-term psychotic disorder, induced psychotic disorder, as well as other psychotic disorders or diseases that have psychotic symptoms, such as bipolar disorder, such as mania ipolyarnom disorder and for the treatment of psychosis in Parkinsona.7 disease. The use of Compound (I) for the manufacture of a medicament for the treatment of psychosis, in particular schizophrenia, or other diseases having �1. Соединение (I) для лечения заболевания центральной нервной системы, отличающееся тем, что Соединение (I) вводят два раза в неделю, еженедельно или раз в две недели в дозе, соответствующей от 20 мг/неделя до 50 мг/неделя в пересчете на свободное основание Соединения (I).2. Соединение (I) по п. 1, где Соединени
